Definition of a novel binding site on CD8 cells for a conserved region of the MHC class Ib molecule Qa1 that regulates IFN-γ expression

Please download to get full document.

View again

of 7
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Categories
Published
Definition of a novel binding site on CD8 cells for a conserved region of the MHC class Ib molecule Qa1 that regulates IFN-γ expression
  0014-2980/01/0101-87$17.50+.50/0© WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2001 Definition of a novel binding site on CD8 cells for aconserved region of the MHC class Ib moleculeQa-1 that regulates IFN-   q  expression Rijian Wang 1, 2 , Sridhar Ramaswamy  3, 4 , Dan Hu 1, 2 and Harvey Cantor 1, 2 1 Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, USA  2 Department of Pathology, Harvard Medical School, Boston, USA  3 Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, USA  4 Department of Medicine, Harvard Medical School, Boston, USA  Natural killer (NK) cells and activated CD8 cells both express cytotoxic activity and producesubstantial levels of IFN-   +  in response to viral and bacterial infections. In the case of NKcells, cellular activation and IFN-   +  expression are regulated by an interaction between NKreceptors and MHC class Ib molecules, including HLA-E/Qa-1. We have used soluble tetra-meric complexes of the murine class Ib molecule Qa-1 to define the significance of this inter-action for CD8 cells. We find that all CD8 cells express a receptor for Qa-1 and that ligationof this receptor by Qa-1 results in up-regulation of IFN-   +  production. Key words:  CD8 / Qa-1 / IFN-   +  / MHC / T cell developmentReceived 26/6/00Revised 15/9/00 Accepted 6/10/00 [I 21008] 1 Introduction CD8 cells play a critical role in the immune response tointracellular pathogens and tumors after TCR ligation byMHC class I / peptide complexes and differentiation tocytotoxic T cells (CTL). CD8 cell activation is alsomarked by production of large amounts of IFN-   +  thatcontributes to the inflammatory component of type 1immunity. Although CD8 cells efficiently produce IFN-   +  insettings that fail to stimulate significant IFN-   +  responsesby CD4 cells [1], the molecular basis of this differencebetween these two major T cell subsets is poorly under-stood.One approach to this problem comes from the similaritybetween the phenotype of NK cells and CD8 cells. Bothexpress cytotoxic activity and produce substantial levelsof IFN-   +  in response to viral and bacterial infections. Inthe case of NK cells, cellular activation and IFN-   + expression are regulated by an interaction between NKreceptors and MHC class Ib molecules including HLA-E/ Qa-1 [2]. We have used soluble tetrameric complexes ofthe murine class Ib molecule Qa-1 to examine whetherthere is a specific interaction between CD8 cells andQa-1. We define a receptor for Qa-1 that is expressed onall CD8 cells and show that ligation of this receptor byQa-1 up-regulates production of IFN-   +  . 2 Results and discussion 2.1 Soluble Qa-1a and Qa-1b proteins refold withQdm and preproinsulin II peptides  in vitro  toproduce soluble tetramers Both Qa-1a and Qa-1b molecules refolded with the Qdmpeptide form soluble tetramers (Fig. 1a, b) with the samerefolding efficiency of about 25%. In addition, both Qa-1alleles refold with a 9-amino acid peptide derived fromthe leader sequence of preproinsulin [3] (Fig. 1c, d) withan efficiency of approximately 10%. In contrast, neitherQa-1 allele refolded with a control peptide derived fromovalbumin (amino acids 257–264) [4] (Fig. 1g, h). 2.2 Binding of Qa-1a and Qa-1b tetramers to DPthymocytes and CD8 cells Thymocytes, splenocytes and lymph node cells fromC57BL/6 (Qa-1b) and C57BL/6.Tla (Qa-1a) congenicmice were incubated with PE-conjugated Qa-1a or Qa-1b tetramers and fluorescein-conjugated anti-CD3, anti-CD4, anti-CD8, anti-B220, and anti-NK1.1 antibodies.FACS analysis revealed that virtually all DP and CD8 SPthymocytes, but not CD4 SP thymocytes, bound tetra-mers formed by both Qa-1 alleles (a and b) (Fig. 2A).Moreover, Qa-1 tetramers bound to all peripheral CD8cells but not to CD4 cells (Fig. 2B). Tetramer binding wasnot restricted by the Qa-1 allele, since Qa-1a and Qa-1btetramers bound equally well to CD8 cells from bothC57BL/6 (Qa-1b) or C57BL/6.Tla (Qa-1a) mice. As Eur. J. Immunol. 2001.  31:  87–93 Definition of a novel binding site on CD8 cells 87  Fig. 1.  Refolding of soluble Qa-1a and Qa-1b molecules withQdm and preproinsulin-derived peptides. Soluble Qa-1aand Qa-1b proteins were purified and refolded in the pres-ence of either Qdm or a nine amino acid peptide derivedfrom the leader sequence of preproinsulin II (ins-II) asdescribed in Sect. 3. Thepeak retentionprofiles of thegel fil-tration results for the refolding reactions are shown. Insertsshow Coomassie blue-stained SDS polyacrylamide gels forpurified monomeric Qa-1 molecules. Panels  a  and  b  showQa-1a and Qa-1b proteins after refolding with the Qdm pep-tide;  c  and  d  show Qa-1a and Qa-1b after refolding with theins-II peptide;  e  and  f  show the purified and biotinylated Qa-1a and Qa-1b molecules formed tetramers in the presenceof streptavidin; and  g  and  h  show that the Qa-1a and Qa-1bmolecules did not refold with the control peptide derivedfrom chicken ovalbumin. Arrow 1 indicates the 13-min reten-tion peaks with molecular mass of about 200 kDa, the pre-dicted molecular mass for Qa-1 tetramers; arrow 2 indicatesthe 18-min retention peaks with molecular mass of about 38kDa, the predicted molecular mass for Qa-1 monomers; andarrow 3 indicates the 24-min retention peaks with molecularmass of about 23 kDa, the predicted molecular mass for thedimerized human   g    2 microglobulin. expected, a proportion of splenic NK1.1 + cells (   ˚  30%),but not B220 + B cells, also bound the Qa-1 tetramers(Fig. 2C, D). Incubation of thymocytes or T cells withheat-denatured Qa-1 tetramers or PE-streptavidin alonedid not result in detectable binding (data not shown). Thelineage-specific binding activity of the Qa-1a and Qa-1btetramers is summarized according to fluorescenceintensity of binding to different T cell subpopulations(Fig. 2E). 2.3 Tetramer binding kinetics and independencefrom CD8 The CD8 coreceptor did not contribute to Qa-1 tetramerbinding because (a) the addition of an anti-CD8 mAb at50-fold excess to tetramer did not inhibit binding to0805B cells (not shown) and (b) the mouse lymphomaS49.33 cell line which expresses both CD8   §    and   g   chains according to FACS analysis (Fig. 3A) did not bindQa-1a/b tetramers and (c) loss of surface CD8 expres-sion secondary to genetic mutation did not affect Qa-1binding: the same proportion of CD3 + thymocytes fromC57BL/6 and C57BL/6 CD8   §    -/- mice bound Qa-1b/Qdmtetramer (not shown).Tetramer binding was greatly reduced after preincuba-tion of T cells with unlabelled tetramer indicating that theinteraction was Qa-1 tetramer-specific and was inde-pendent of the Qa-1 allele: Qa-1a binding was efficientlyblocked by cold Qa-1b tetramer and vice versa (notshown). We examined the kinetics of the interaction withQa-1 tetramer using the 0805B BALB/c CD8 + CD4 - CTLline specific for a  lacZ  -derived peptide [5]. 0805B cells(Fig. 3A, panels 1–3) bound Qa-1a/b tetramers contain-ing either Qdm (Fig. 3A, panel 2) or preproinsulin pep-tides (Fig. 3A, panel 3). Fluorescence-conjugated mAbstaining showed that virtually all 0805B cells expressCD3 and CD8, but not CD4 or NK1.1 (data not shown).Double staining with FITC-conjugated mAb and PE-labeled Qa-1 tetramer confirmed that 0805B cellsexpress CD8 but not CD4; like CD4 + 8 + thymocytes, bind-ing was not inhibited by anti-CD8 antibody (data notshown). To determine whether binding of Qa-1 tetramersto CD8 + thymocytes and T cells is a receptor-mediatedprocess, 0805B CD8 cells were incubated with coldQa-1 tetramers before addition of PE-conjugated Qa-1tetramer. Qa-1 tetramer binding to CD8 T cells displayedtypical receptor-ligand kinetics, including saturation ofbinding at high concentration of ligand and specific inhi-bition by cold ligand. Tetramer binding increased untilthe concentration of PE-conjugated tetramer was 200ng/ml and then plateaued, indicating saturable binding(Fig. 3C, D). Cross-blocking experiments indicated thattetramer binding by cold ligand was neither Qa-1 allele-specific nor peptide dependent. 88 R. Wang et al. Eur. J. Immunol. 2001.  31:  87–93  Fig. 2.  Lineage-specific binding of Qa-1a and Qa-1b tetramers to T cells. Flow cytometric analysis of C57BL/6 and C57BL/6.Tlathymocytes, lymph node and spleen cells after incubation with Qa-1a/Qdm, Qa-1b/Qdm, Qa-1a/ins-II, and Qa-1b/ins-II tetra-mers. (A) and (B) show the FACS histogram of the thymocytes after incubation with Qa-1a/Qdm and Qa-1b/Qdm tetramers. (C)and (D) show FACS scatter plot data of peripheral lymphocytes stained with Qa-1a/Qdm and Qa-1b/Qdm tetramers and differentmAb. Panel E summarizes tetramer binding of different cell populations of Qa-1a (     Æ  ) and Qa-1b (     |     ), according to fluorescenceintensity. 2.4 Qa-1a tetramer binding co-stimulates IFN-   q expression by CD8 cells We tested the functionalconsequences of the interactionbetween Qa-1 and CD8 cells. Addition of Qa-1b/Qdmnatural, but not denatured, tetramer to anti-CD3-stimulated 0805B CD8 + cells increased the IFN-   +   response by 4–6 fold (Fig. 4A). Addition of Qa-1b/Qdmtetramer, but not denatured tetramer or monomer, alsoenhanced IFN-   +    response of CD8 cells from female HYTCR transgenic mice to the HY antigen four to fivefold(Fig. 4B). Qa-1-dependent enhancement of IFN-   +    pro-duction was antigen specific since soluble Qa-1 tetra-mer, but not monomer, enhanced the IFN-   +    response offemale HY-TCR CD8 cells to HY peptide presented APCby five to sixfold (Fig. 4C). These findings suggest thatexpression of Qa-1 on activated APC might normallyserve to enhance IFN-   +    expression by CD8 cells. Thishypothesis received additional support from the obser-vation that addition of anti-Qa-1b mAb (but not anisotype-matched control) to cultures of CD8 cells and(Qa-1 +  ) activated B cells inhibited IFN-   +    production bymore than 90% (Fig. 4D).Previous findings have indicated that Qa-1 can regulateinnate immune responses through interaction with inhibi-tory and activating receptors on NK cells [6, 7]. Our find-ings confirm binding of Qa-1/peptide tetramers tosplenic NK cells. However, we also find that thymocytesacquire binding activity for a conserved portion of Qa-1/ peptide complexes at the DP stage of thymic develop-ment and maintain this binding site during CD8 but notCD4 cell development in the thymus and peripheral tis-sues. Binding of Qa-1/peptide tetramer to CD8 cells is asaturable and inhibitable process that displays kineticstypical of a receptor-ligand interaction. Since binding toQa-1 is neither peptide- nor Qa-1 allele-specific anddoes not depend on the CD8-coreceptor, it is likely to bemediated by a conserved (non-clonal) receptor that isexpressed during development of CD8 cells that mayregulate the development and/or function of this T cellsubset. Indeed, one functional consequence of the inter-action between this receptor and Qa-1/peptide com-plexes expressed on the surface of APC is enhancedproduction of IFN-   +    .The molecular identity of the Qa-1/peptide receptor onCD8 cells is not established in these studies. Although Eur. J. Immunol. 2001.  31:  87–93 Definition of a novel binding site on CD8 cells 89  Fig. 3.  Binding kinetics of Qa-1 tetramer to CD8 cells. 0805B cells (CD8 +  ) and S49 (CD8 +  ) cells were stained with Qa-1b/Qdm tet-ramers.(A) Immunofluorescenceof 0805Bcellsand S49cells after incubationwithQa-1b tetramers: fluorescencecontrol (panels1 and 4); Qa-1b/Qdm tetramer (panels 2 and 5); Qa-1b/ins-II tetramer (panels 3 and 6). (B) Double staining of the cells with Qa-1b/Qdm tetramer and mAb against TNP,CD3,CD4, or CD8.(C)0805Bcells wereincubated withincreasing concentrations of un-labeled Qa-1b/Qdm tetramer before addition of a fixed amount of PE-conjugated Qa-1b/Qdm tetramer. (D) 0805B cells wereincubated with a fixed amount of unlabeled Qa-1b/Qdm tetramer before addition of increasing concentrations of PE-conjugatedQa-1b/Qdm tetramer: saturation binding, kinetics, non-specific binding and specific inhibition are shown. Qa-1 binds to the NK receptor CD94/NKG2A and CD94/ NKG2C, it is unlikely that these receptors account forbinding activitysince onlya smallproportionof CD8cells(less than 10%) express these receptors before or afteractivation [8, 9]. Another candidate receptor is theNKG2D-DAP10 receptor complex, which serves asreceptor for the stress-inducible MHC-like moleculeMICA [10, 11]; however, COS7 cells successfully trans-fected with murine NKG2D do not acquire binding activ-ity for Qa-1/peptide tetramers (data not shown). It islikely that the CD8:Qa-1 interaction documented in thestudies reported here may reflect the activity of an as yetundefined receptor(s) expressed during CD8 develop-ment. Definition of this receptor should allow additionalinsight into the molecular basis of the CD8 phenotypeand the developmental relationship of these cells tothose of the NK lineage. 3 Materials and methods 3.1 Animals and cell lines C57BL/6J (Qa-1b), C57BL/6-Tla (Qa-1a), A.J. (Qa-1a),BALB/c (Qa-1b), and HY transgenic (C57BL/6 background)mice were purchased from The Jackson Laboratory (BarHarbor, ME) and maintained in the Dana-Farber CancerInstitute Animal Facility. 0805B cells (a BALB/c   g    -galactosidase-specific CD8 + cytotoxic T cell line), p815 (aDBA/2 mastocytoma cell line), CPAG60 (p815 cells stablytransfected with pSP control vector) and p13.1 (p815 cellsstably transfected with pSP vector expressing   g    -galactosidase) [5] were incubated in RPMI 1640 mediumsupplemented with 10% fetal bovine serum, 100 U/ml peni-cillin, 50   ?  g/ml streptomycin, and 50   ?  M   g    -merca-ptoethanol.90 R. Wang et al. Eur. J. Immunol. 2001.  31:  87–93  Fig. 4.  Effect of Qa-1 tetramer binding on IFN-   +   production by CD8 cells. (A) IFN-   +   production of 0805B CD8 cells in the presenceof anti-CD3 and Qa-1/Qdm tetramer. 0805B cells (2×10 4  ) were incubated with 12.5 ng/ml anti-CD3 mAb for 48 h in the absenceor presence of Qa-1b/Qdm un-denatured or denatured tetramer before supernatants were assessed for IFN-   +   production byELISA. (B) IFN-   +   production of CD8 cells from female anti-HY TCR tg mice incubated with syngeneic female LPS-activated Bcells with the indicated preparation of Qa-1/Qdm tetramer. (C) IFN-   +   production by CD8 cells from female anti-HY TCR tg miceincubated with syngeneic female LPS-activated B cells with or without HY peptide and Qa-1/Qdm tetramer or monomer. (D) CD8cells from C57BL/6 mice incubated with syngeneic LPS-activated B cell blasts in the presence of mAb against Qa-1b or anisotype-matched control mAb (anti-TNP) before assessment of IFN-   +   production by ELISA. 3.2 Antibodies and reagents Cychrome-conjugated 135–2C11 (anti-CD3  4   ), fluoresceinisothiocyanate (FITC)-conjugated GK1.5 (anti-CD4), FITC-anti CD3, Ly-2 (anti-CD8), PK136 (anti-NK1.1), DX5 (anti-NK), M1/70 (anti-Mac-1), RA3–6B2 (anti-B220) mAb andsodium azide-free, endotoxin-free anti-Qa-1b, anti-TNP(isotypic control) and 17A2 (anti-CD3 complex) mAb werepurchased from PharMingen (San Diego, CA). Fetal calfserum,   g  -mercaptoethanol, L-arginine, aprotinin, pepstatin A, glutathione reduced form, glutathione oxidized form, dis-odium EDTA and urea were purchased from Sigma ChemicalCompany (St. Louis, MO). Qdm and preproinsulin peptideswere synthesized by the Biopolymers laboratory, HarvardMedical School. 3.3 Generation of Qa-1a and Qa-1b tetramers The Qa-1a expression vector pET-23a/Qa-1a was con-structed using RT-PCR to amplify a truncated Qa-1a mole-cule (amino acids 1–279) from a cDNA library prepared fromC57BL/6-Tla mouse splenocytes. The oligonucleotide prim-ers (5’-gcg cat atg AGT TCA CAT TCG CTG-3’ and 5’-actaag ctt GGA TGG AGG AGG CTC-3’) were used for theamplification of the Qa-1a cDNA (Nde I and BamH I sitesunderlined). After digestion with Nde I and BamH I, the Qa-1a PCR fragment was cloned into Nde I/BamH I digestedpET-23a/Qa-1b vector [12]. The integrity of the Qa-1a cDNA and the biotinylation site in the pET-23a vector was verifiedby DNA sequencing. The pET-23a/Qa-1a and pET-23a/Qa-1b vectors [6] were transformed into  Escherichia coli   strainEur. J. Immunol. 2001.  31:  87–93 Definition of a novel binding site on CD8 cells 91
Similar documents
View more...
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks